tetano
Editor, Senior Moderator
J Infect Dis. 2012 Aug 16. [Epub ahead of print]
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by aetiology.
Beck CR, McKenzie BC, Hashim AB, Harris RC; UNIIC Study Group, Nguyen-Van-Tam JS.
Source
Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom.
Abstract
Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and meta-analyses to assess the evidence for influenza vaccination in this group, and report our results by aetiology. Meta-analyses showed significantly lower odds of influenza-like illness post vaccination in HIV patients, cancer patients and transplant recipients and of laboratory confirmed influenza in HIV patients, compared to placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV patients, cancer patients and transplant recipients, compared to immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between aetiologies. Limited evidence of a transient increase in viraemia and a decrease in CD4% in HIV patients was found although not accompanied by worsening of clinical symptoms. Clinical judgement remains important when discussing the benefits and safety profile with immunocompromised patients.
PMID:
22904335
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22904335
Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by aetiology.
Beck CR, McKenzie BC, Hashim AB, Harris RC; UNIIC Study Group, Nguyen-Van-Tam JS.
Source
Division of Epidemiology and Public Health, University of Nottingham, Nottingham, United Kingdom.
Abstract
Many national guidelines recommend annual influenza vaccination of immunocompromised patients, although the decision to vaccinate is usually at clinical discretion. We conducted a systematic review and meta-analyses to assess the evidence for influenza vaccination in this group, and report our results by aetiology. Meta-analyses showed significantly lower odds of influenza-like illness post vaccination in HIV patients, cancer patients and transplant recipients and of laboratory confirmed influenza in HIV patients, compared to placebo or no vaccination. Pooled odds of seroconversion and seroprotection were typically lower in HIV patients, cancer patients and transplant recipients, compared to immunocompetent controls. Vaccination was generally well tolerated, with variation in mild adverse events between aetiologies. Limited evidence of a transient increase in viraemia and a decrease in CD4% in HIV patients was found although not accompanied by worsening of clinical symptoms. Clinical judgement remains important when discussing the benefits and safety profile with immunocompromised patients.
PMID:
22904335
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/22904335